ADVFN - Advanced Financial Network.
HOME» NYSE » J » JNJ Stock Price » JNJ Stock News

Johnson & Johnson Share News

 Johnson & Johnson Stock Price
JNJ Stock Price
 Johnson & Johnson Stock Chart
JNJ Stock Chart
 Johnson & Johnson Stock News
JNJ Stock News
 Johnson & Johnson Company Information
JNJ Company Information
 Johnson & Johnson Stock Trades
JNJ Stock Trades

J&J CEO: Will Make Any Changes Needed After Recall

DOW JONES NEWSWIRES Johnson & Johnson's (JNJ) chief executive vowed to make whatever changes are needed for its manufacturing processes to meet consumers' expectations and the company's own standards, saying it has hired independent quality experts to help. The company recalled about 1,500 lots of bottled products last week, including pediatric versions of Tylenol, Motrin, Zyrtec and Benadryl. Its McNeil Consumer Healthcare unit said it was withdrawing the over-the-counter products, starting late last Friday, because of manufacturing problems at its Fort Washington, Pa., plant In an open letter Friday to all those who use J&J products on the firm's corporate blog, Chairman and Chief Executive Bill Weldon called the recalls a disappointment to him and the rest of the company and its workers. "I have been assured that the chance of a serious medical event from the recalled products is remote," he said. "Even so, this does not give us comfort; one of our companies has let you down." He reiterated that McNeil suspended manufacturing at the Pennsylvania plant and has hired independent quality experts to help the facility return to the proper standards and also reevaluate the systems and manufacturing processes across the organization. He ended the note by saying the company "will work hard to earn back your confidence." A House committee said earlier this week it is opening an investigation into conflicting accounts of what had prompted the recall, as well as how the company handled consumer complaints about foreign matter in the bottles. Johnson & Johnson shares were up 0.2% at $63.42 in after-hours trading. The stock is down modestly so far this year. Johnson & Johnson blog: -By Joan E. Solsman, Dow Jones Newswires; 212-416-2291;

Stock News for Johnson & Johnson (JNJ)
11/25/201516:22:02How Johnson & Johnson Spent $71 Billion in 12 Months
11/25/201509:04:03Johnson & Johnson's Latest FDA Approval Could Spell Problems...
11/24/201520:44:00Share A Photo, Give Back In A Snap
11/24/201513:01:09Statement of Changes in Beneficial Ownership (4)
11/24/201507:41:03This Metric Implies That It Might Be Time to Buy Big Pharma Stocks
11/23/201508:46:033 Dividend Stocks You Don't Have to Babysit
11/22/201509:04:033 Top Stocks for Retirees to Buy
11/22/201507:00:093 Specialty-Drug Makers Trying to Spark Investor Interest...
11/21/201512:04:023 Healthcare Stocks You Don't Have to Babysit
11/19/201523:30:00Horizon Pharma Withdraws Bid for Depomed
11/18/201508:11:03These 5 Companies Own 491 Million Shares of Johnson & Johnson
11/17/201516:30:00Johnson & Johnson Announces $1.75 Million Donation to Save the...
11/17/201507:39:03Better Dividend Stock: Johnson & Johnson vs. Eli Lilly and Company
11/16/201508:42:04Best Dividend Stocks for 2016
11/15/201515:18:04Millennials Are Investing More in Stocks Than You May Think
11/15/201510:15:03The Best Stocks in Conglomerates
11/13/201515:38:025 Things Johnson & Johnson Wants You to Know
11/13/201515:00:00Horizon Holders Approve Stock Issuance for Depomed Bid
11/11/201508:01:03Should Healthcare Dividend Hunters Target AbbVie or Johnson...
11/10/201507:45:00Johnson & Johnson Inc. Named One of Canada's Top 100 Employers

Johnson & Johnson and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations